Trevi Therapeutics (TRVI) Stock Price, News & Analysis

Company Overview

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy. In addition to its TTX program, Trevi maintains a pipeline of preclinical and discovery-stage assets aimed at broadening treatment options for patients with refractory pain syndromes.

Headquartered in San Diego, California, Trevi Therapeutics conducts research and development activities at its U.S. facilities and collaborates with academic institutions and contract research organizations to advance its clinical candidates. The company’s leadership team combines expertise in pharmaceutical development, regulatory affairs and commercialization strategy to guide its growth as a specialty biopharmaceutical innovator.

Key Stats

• Today's Range: $8.01 to $9.70
• 50-Day Range: $5.86 to $9.75
• 52-Week Range: $2.36 to $9.92
• Volume: 3.62 million shs
• Average Volume: 2.75 million shs
• Market Capitalization: $1.00 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.75
• Consensus Rating: Buy

Trevi Therapeutics Stock Analysis - MarketRank™

Trevi Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 503rd out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Buy

Consensus Rating

Trevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Trevi Therapeutics has a consensus price target of $21.75, representing about 163.6% upside from its current price of $8.25.

Amount of Analyst Coverage

Trevi Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.49) to ($0.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Trevi Therapeutics is -19.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Trevi Therapeutics is -19.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Trevi Therapeutics has a P/B Ratio of 6.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.74% of the float of Trevi Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Trevi Therapeutics has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Trevi Therapeutics has recently increased by 15.53%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Trevi Therapeutics does not currently pay a dividend.

Dividend Growth

Trevi Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.74% of the float of Trevi Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Trevi Therapeutics has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Trevi Therapeutics has recently increased by 15.53%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.39

News Sentiment

Trevi Therapeutics has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Trevi Therapeutics this week, compared to 5 articles on an average week.

Search Interest

8 people have searched for TRVI on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.30% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TRVI Stock Analysis - Frequently Asked Questions

How have TRVI shares performed this year?

Trevi Therapeutics' stock was trading at $4.12 at the beginning of the year. Since then, TRVI stock has increased by 100.2% and is now trading at $8.25.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced its earnings results on Thursday, August, 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01.
Read the conference call transcript.

When did Trevi Therapeutics IPO?

Trevi Therapeutics (TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

Who are Trevi Therapeutics' major shareholders?

Top institutional investors of Trevi Therapeutics include Rubric Capital Management LP (7.01%), Vivo Capital LLC (3.69%), Alliancebernstein L.P. (3.52%) and Octagon Capital Advisors LP (3.02%). Insiders that own company stock include David P Meeker, Thomas Sciascia, Jennifer L Good, Farrell Simon and Lisa Delfini.
View institutional ownership trends.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Trevi Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include JPMorgan Chase & Co. (JPM), Predictive Oncology (POAI), Ford Motor (F), Tesla (TSLA), Meta Platforms (META), Abbott Laboratories (ABT) and Bank of America (BAC).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRVI
• CIK: 1563880
• Web: www.trevitherapeutics.com
• Phone: (203) 304-2499
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Trevi Therapeutics: $21.75
• High Price Target: $27.00
• Low Price Target: $18.00
• Potential Upside/Downside: +163.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.91 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.44%
• Return on Assets: -38.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.42
• Quick Ratio: 22.42

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.30 per share
• Price / Book: 6.35

Miscellaneous

• Outstanding Shares: 121,777,000
• Free Float: 99,492,000
• Market Cap: $1.00 billion
• Optionable: Optionable
• Beta: 0.71